0.44
+7.87%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jaguar Health
From its filings with the US Securities and Exchange Commission
Jaguar Health is based in San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker JAGX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $11.5m and a net loss of $53.6m. At that date it held total assets of $38.3m and shareholders' equity of −$18.7m.
Jaguar Health, Inc. (“Jaguar”), in conjunction with Jaguar family company Napo Pharmaceuticals, Inc. (“Napo”), develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states. Jaguar family companies Napo and Napo Therapeutics, S.p.A., an Italian corporation Jaguar was established in Milan, Italy in 2021, are focused on expanding global crofelemer access and are developing new therapies for orphan and rare GI conditions. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications.
Napo’s crofelemer 125 mg delayed-release tablets (Mytesi) is an FDA (the U.S. Food and Drug Administration) approved prescription drug for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In January 2026, following Napo’s entry into a United States ("US") licensing agreement with an affiliate of privately held Future Pak, LLC (“Future Pak”), Future Pak became the exclusive marketer for Mytesi as well as the tablet formulation for animal health, Canalevia-CA1, which is Jaguar’s crofelemer prescription drug for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar was provided with $16 million of non-dilutive capital in January 2026 upon closing of the agreement with Future Pak, with an additional $2 million due to Jaguar upon completion of post-closing conditions.
Quoted from its 10-K, filed 7 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 May 2015
- Employees
- 47
- Website
- jaguar.health ↗
- Head office
- 200 PINE STREET SUITE 400, SAN FRANCISCO, CA, 94104
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. James BochnowskiIndependent Chairman of the Board, since 2014$132,577
- Ms. Lisa ContePresident, Chief Executive Officer, Director, since 2013$875,320
- Ms. Carol LizakChief Financial Officer
- Dr. Pravin ChaturvediChief Scientific Officer$646,627
- Mr. Jonathan WolinChief of Staff, General Counsel, Chief Compliance Officer$574,207
- Mr. Ian WendtChief Commercial Officer$557,901
- Dr. Steven KingChief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary$515,902
- Dr. Anula JayasuriyaIndependent Director$68,877
- Mr. John MicekIndependent Director$95,244
- Mr. Jonathan SiegelIndependent Director$97,744
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jaguar Health focuses on sustainable gastrointestinal products from rainforest plants for global markets.
- Mytesi is an antidiarrheal for HIV/AIDS patients on antiretroviral therapy with a clear market need.
- Napo Pharmaceuticals subsidiary develops human GI pharmaceuticals using traditional rainforest plant knowledge.
Weaknesses
- Jaguar Health employs only 29 full-time employees, limiting operational capacity.
- The company's IPO was in 2015, indicating a relatively young market presence.
- Mytesi targets a specific HIV/AIDS patient segment with limited broader market reach.
Opportunities
- Expanding Mytesi use to other gastrointestinal conditions beyond HIV/AIDS could increase market size.
- Napo Pharmaceuticals can leverage traditional rainforest plant knowledge for new product development.
- Global commercialization of Canalevia, Equilevia, Neonorm Calf, and Neonorm Foal offers growth potential.
Threats
- Competition from established pharmaceutical companies in the GI sector poses a risk to market share.
- Regulatory challenges in global markets may delay product approvals and commercialization.
- The reliance on specific rainforest plant sources could lead to supply chain vulnerabilities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.